Celling out
By Tali Woodward,
San Francisco Bay Guardian
| 04. 06. 2005
The directors of stem cell institute have direct ties to biotech firms that stand to gain
Members of the panel charged with overseeing California's stem cell research program _ and the $3 billion in taxpayer-financed grants it will distribute _ work for, have investments in, and are personally connected to the pharmaceutical and biotech companies poised to benefit from the grants.
Critics have long said that the structure of the panel, set up by last fall's Proposition 71, makes a mockery of its official name: the Independent Citizens Oversight Committee. The measure virtually guaranteed members of the 29-member board would have ties to the biotech industry. It was one of the main objections of people who were questioning the wisdom of Prop. 71 prior to the election (see "Cell Divide," 9/29/04).
see moreBut after several big biotech insiders were appointed to the committee in January, concern that those ties could skew the way money is doled out has only increased. Berkeley public interest attorney Charles Halpern, who has been closely monitoring the panel, told the Bay Guardian, "The basic principle is this: anyone handing out public funds should have undivided loyalty to the public interest, and the...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...